Key Points
- CEO Brian Culley purchased 15,000 shares at an average price of $1.62 on March 12 for a total of $24,300, increasing his holdings to 255,516 shares (a 6.24% rise).
- Lineage reported quarterly EPS of $0.00 (beat the -$0.07 estimate) and revenue of $6.61 million (well above the $1.96 million estimate), but still showed a deeply negative net margin (436.47%) and negative return on equity (76.13%).
- Analysts are generally bullish—three firms have Buy ratings, D. Boral Capital raised its target to $3, and the stock's average analyst target sits at about $5.00.
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) CEO Brian Culley acquired 15,000 shares of the business's stock in a transaction on Thursday, March 12th. The stock was acquired at an average price of $1.62 per share, with a total value of $24,300.00. Following the transaction, the chief executive officer directly owned 255,516 shares of the company's stock, valued at $413,935.92. This represents a 6.24% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Lineage Cell Therapeutics Price Performance
Shares of NYSEAMERICAN LCTX traded up $0.03 during trading on Friday, hitting $1.61. 1,028,718 shares of the company were exchanged, compared to its average volume of 1,158,415. The company has a market cap of $399.79 million, a price-to-earnings ratio of -5.73 and a beta of 1.74. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.37 and a 1 year high of $2.09. The firm's fifty day moving average price is $1.73 and its 200 day moving average price is $1.66.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last announced its quarterly earnings results on Thursday, March 5th. The company reported $0.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.07) by $0.07. The business had revenue of $6.61 million during the quarter, compared to the consensus estimate of $1.96 million. Lineage Cell Therapeutics had a negative net margin of 436.47% and a negative return on equity of 76.13%. On average, research analysts forecast that Lineage Cell Therapeutics, Inc. will post -0.12 earnings per share for the current year.
Analyst Ratings Changes
Several research firms recently weighed in on LCTX. D. Boral Capital lifted their price objective on Lineage Cell Therapeutics from $2.00 to $3.00 and gave the stock a "buy" rating in a report on Friday, March 6th. HC Wainwright restated a "buy" rating on shares of Lineage Cell Therapeutics in a research report on Friday, March 6th. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $5.00.
Get Our Latest Stock Report on LCTX
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Catalyst Funds Management Pty Ltd purchased a new position in Lineage Cell Therapeutics during the second quarter worth $75,000. Royal Bank of Canada boosted its stake in shares of Lineage Cell Therapeutics by 1,578.9% during the first quarter. Royal Bank of Canada now owns 528,656 shares of the company's stock valued at $237,000 after acquiring an additional 497,168 shares during the last quarter. Hudson Bay Capital Management LP purchased a new stake in Lineage Cell Therapeutics during the 4th quarter worth about $124,000. Rhumbline Advisers raised its stake in Lineage Cell Therapeutics by 9.9% in the 1st quarter. Rhumbline Advisers now owns 201,447 shares of the company's stock valued at $91,000 after purchasing an additional 18,092 shares during the last quarter. Finally, WINTON GROUP Ltd acquired a new position in Lineage Cell Therapeutics in the 2nd quarter valued at about $69,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.
About Lineage Cell Therapeutics
(
Get Free Report)
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.
Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
